Crown Bioscience Names Laurie Heilmann Chief Business Officer; Executive Leader Brings Expertise In Global Strategy And Commercial Leadership To The Role
Published: Sep 27, 2017
SANTA CLARA, Calif., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, today announces the appointment of Laurie Heilmann as Chief Business Officer. Since 2014, Heilmann has served as Crown Bioscience’s Sr. Vice President; Global Strategy, Business Development, Marketing.
“Laurie is the ideal leader for our strategic commercial operations, possessing a diverse therapeutic background and over three decades of experience aligning sales and marketing with R&D to steer company strategy,” said Jean-Pierre Wery, Ph.D., Crown Bioscience Chief Executive Officer. “As Sr. Vice President; Global Strategy, Business Development, Marketing, Laurie led Crown Bioscience through three years of sustained, exponential growth and guided expansion of our innovative scientific technology platform. I am excited to continue working closely with Laurie to provide our clients with the insight and understanding they need to advance their preclinical research projects.”
“I am honored to be assuming the role of Chief Business Officer at Crown Bioscience,” said Laurie Heilmann, former Sr. Vice President; Global Strategy, Business Development, Marketing.at Crown Bioscience. “I look forward to continuing to work with Dr. Wery and our talented, dedicated team of scientists, business development and marketing professionals building our translational technology platform to help our clients address global health challenges.”
Laurie is an active member of numerous industry organizations, and holds a bachelor’s degree in science and business administration. She possesses a therapeutic and life science technology background which includes cardiovascular, oncology, immunology and metabolic disease and over three decades of global experience aligning sales and marketing with R&D to steer company strategy. As Chief Business Officer, Laurie will be responsible for world-wide sales, strategy and marketing at Crown Bioscience.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Crown Bioscience Inc. email@example.com